Paola trial nejm

Author: bytg

August undefined, 2024

WebIn the primary analysis of PAOLA-1/ENGOT-ov25 (NCT02477644), adding olaparib to maintenance bev after first-line platinum-based chemotherapy with bev led to a significant progression-free survival benefit in advanced HGOC pts (HR 0.59; 95% CI 0.49 -0.72) (Ray-Coquard et al. NEJM 2024); PFS2 was immature. WebMay 28, 2024 · Conclusions: In the PAOLA-1 study, maintenance olaparib + bev provided a PFS and PFS2 benefit over pbo + bev in HRD+ pts, irrespective of FIGO stage and residual disease after upfront surgery. Clinical trial information: NCT02477644. PFS and PFS2 by FIGO stage in HRD+ pts in PAOLA-1. NE, not estimable.

OlympiA phase III: OS results of olaparib in gBRCAm Breast …

WebJan 20, 2024 · PAOLA-1 Trial. Jan 20, 2024. Thomas Herzog, MD. EP: 1.Genetic Testing for Ovarian Cancer. EP: 2.Role of Maintenance Therapy in Ovarian Cancer. ... Data from the … overalls fit

Login to your account - The Lancet Oncology

WebMar 21, 2024 · After long-term follow-up, olaparib (Lynparza) maintenance therapy demonstrated progression-free survival (PFS) benefit in almost half (48%) of the patients with ovarian cancer compared with 21% for those who received placebo, including consistent benefit in high- and low-risk patients. 1 WebDec 11, 2024 · The objective of this study is to prove that treatment with primary cytoreductive surgery in combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive surgery without HIPEC (standard arm) with acceptable morbidity, in patients with FIGO stage III epithelial ovarian cancer who are eligible for … WebMay 28, 2024 · Background: The Phase III MONALEESA-3 trial (NCT02422615) previously demonstrated a statistically significant improvement in OS with RIB, a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), plus FUL compared with placebo (PBO) plus FUL as first-line (1L) or second-line (2L) treatment in postmenopausal pts with HR+/HER2− ABC … rallye annonay

Homologous recombination repair mutation gene panels (excluding

WebPurpose: In the initial PALOMA-2 ( NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. WebJun 2, 2024 · 5562. Background: In the Phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644), maintenance olaparib plus bevacizumab (bev) provided a significant progression-free survival (PFS) benefit, compared with placebo plus bev, in patients (pts) with newly diagnosed advanced ovarian cancer in response after platinum-based … overalls fashion menWebSep 28, 2024 · The PAOLA-1/ENGOT-ov25 trial did not include patients with no response to first-line chemotherapy, but this is a small group. This trial is a significant step forward in treatment for these women.” Other positive trials of PARP inhibitors in advanced ovarian cancer are presented at the ESMO Congress 2024. rallye antibes 2022 forum

"WebOlaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial Authors " - Paola trial nejm

Paola trial nejm

Olaparib plus Bevacizumab as First-Line Maintenance in …

Web2416 n engl j med 381;25 nejm.orgDecember 19, 2024 The authors’ full names, academic de-grees, and affiliations are listed in the ... PAOLA-1 trial was conducted in 11 countries. WebBackground PAOLA-1/ENGOT-ov25 (NCT02477644) is a phase III trial in pts with newly diagnosed, FIGO stage III‒IV HGOC.

Did you know?

WebIn the PAOLA-1/ENGOT-ov25 (NCT02477644) primary analysis, adding ola to maintenance bev after first-line (1L) platinum-based chemotherapy (PBC) + bev led to a significant progression-free survival (PFS) benefit in AOC (HR 0.59, 95% CI 0.49–0.72; P<0.001), particularly in pts with homologous recombination deficiency (HRD+; BRCA1/2 mutation … WebIntroduction In the Phase III PAOLA-1/ENGOT-ov25 trial ([NCT02477644][1]), adding maintenance olaparib to bevacizumab improved progression-free survival (PFS) in …

WebSep 10, 2024 · The investigators concluded: “In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance … WebSep 28, 2024 · Isabelle L. Ray-Coquard of the Medical Oncology, Centre Léon Bérard in Lyon, GINECO group France presented findings from the PAOLA-1/ENGOT-ov25 trial, …

WebAug 21, 2024 · Background: There is a need for novel therapies for relapsed or refractory multiple myeloma, and B-cell maturation antigen (BCMA) is a validated target. Teclistamab is a bispecific antibody that binds BCMA and CD3 to redirect T cells to multiple myeloma cells. The aim of the MajesTEC-1 study was to evaluate the safety, tolerability, and … WebPAOLA-1/ENGOT-ov25 ([NCT02477644][1]) is the first Phase III trial to evaluate the efficacy and safety of a PARP inhibitor with bevacizumab as first-line maintenance …

WebDec 19, 2024 · BRCA. BRCA mutations (median progression-free survival, 37.2 vs. 17.7 months), and 0.43 (95% CI, 0.28 to 0.66) in patients with HRD-positive tumors that did …

WebSep 2, 2024 · Trial Design and Oversight We conducted a phase 3 pragmatic, open-label, parallel-group randomized controlled trial at 22 U.K. NHS hospitals following independent ethics committee approval... rallye antibes 2021WebDec 19, 2024 · Conclusions: Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-free survival than those who received placebo, regardless of the presence or absence of homologous-recombination deficiency. rallye antibes 2022 classementWebSep 10, 2024 · One of the most important aspects of the design of PAOLA-1 is the control arm of the trial, which received active maintenance with bevacizumab, whereas in each … overalls fashionableWebPAOLA-1 is the first and only phase 3 trial to investigate a PARP inhibitor combination regimen against an active and established maintenance therapy: bevacizumab 1-5 In women with HRD-positive * advanced ovarian cancer, following complete or partial response to first-line platinum-based chemotherapy + bevacizumab1 rallye antibes 2000WebIn the primary analysis of PAOLA-1/ENGOT-ov25 (NCT02477644), adding olaparib to maintenance bev after first-line platinum-based chemotherapy with bev led to a significant progression-free survival benefit in advanced HGOC pts (HR 0.59; 95% CI 0.49 -0.72) (Ray-Coquard et al. NEJM 2024); PFS2 was immature. overalls flowersWebJun 23, 2015 · Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, … rallye antibes 2021 resultatsWeb814MO - Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC) Presenter: Yvette Drew Session: Mini Oral - Gynaecological cancers 2 Resources: Abstract Slides Webcast 18 Sep 2024 overalls fishing